Warner Chilcott Plc offers potential acquirers the chance to buy a company that throws off more cash from selling contraceptives and colitis treatments than any specialty drugmaker in the world.
Actavis Inc. stands to return 17 percent more to shareholders by acquiring birth-control drugmaker Warner Chilcott Plc than selling itself.
Actavis Inc., the largest U.S. maker of generic drugs by market value, agreed to acquire Warner Chilcott Plc for about $5 billion excluding net debt in a deal to expand in women’s health and urology.
Actavis Inc., the largest U.S. maker of generic drugs by market value, said it’s in “early stage discussions” to buy Warner Chilcott Plc, the drugmaker that unsuccessfully pursued a sale last year.
Warner Chilcott Plc is weighing options including a possible sale after receiving interest from strategic and private-equity buyers, according to people with knowledge of the matter. The shares jumped in early trading.